Avoid concomitant use of strong or moderate CYP3A inhibitors with Elacestrant.
Elacestrant is a CYP3A4 substrate. Concomitant use of a strong or moderate CYP3A4 inhibitor increase elacestrant exposure, which may increase the risk of adverse reactions of Elacestrant.
Avoid concomitant use of strong or moderate CYP3A inducers with Elacestrant.
Elacestrant is a CYP3A4 substrate. Concomitant use of a strong or moderate CYP3A4 inducer decreases elacestrant exposure, which may decrease effectiveness of Elacestrant.
Reduce the dosage of P-gp substrates per their Prescribing Information when minimal concentration changes may lead to serious or life-threatening adverse reactions.
Elacestrant is a P-gp inhibitor. Concomitant use of Elacestrant with a P-gp substrate increased the concentrations of P-gp substrate. which may increase the adverse reactions associated with a P-gp substrate.
Reduce the dosage of BCRP substrates per their Prescribing Information when minimal concentration changes may lead to serious or life-threatening adverse reactions.
Elacestrant is a BCRP inhibitor. Concomitant use of Elacestrant with a BCRP substrate increased the plasma concentrations of BCRP substrate, which may increase the adverse reactions associated with a BCRP substrate.
from FDA,2023.05